Study aims to pinpoint ideal imatinib dose for GIST patients
NCT ID NCT07614841
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at 328 patients with intermediate or high-risk gastrointestinal stromal tumors (GISTs) who took imatinib after surgery. The goal was to find the best dose that balances effectiveness in preventing tumor return with the risk of side effects. Researchers measured drug levels in the blood and tracked how long patients stayed cancer-free.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- imatinib
- What this could lead to
- If successful, this could help doctors find the safest and most effective dose of imatinib for GIST patients after surgery.
- What could go wrong
- This is an observational study, not a controlled trial, so results may not prove cause and effect. The findings may not apply to all GIST patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Brain-Cancer drug take on a stubborn stomach tumor?
- New hope for stubborn GIST: experimental drug DCC-2618 enters safety testing
- New drug cocktail targets tough stomach cancer in Last-Resort patients
- New hope for rare stomach cancer: chemo drug shows promise in early trial
- New oral paclitaxel trial offers hope for Hard-to-Treat GIST
- Chemotherapy drug paclitaxel tested for Hard-to-Treat GIST